Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Current CML treatments: which TKI to choose?

Gianantonio Rosti • 13 Jun 2019
EHA 2019
Chronic Myeloid Leukemia Leukemia Bosutinib Dasatinib Imatinib Nilotinib Ponatinib

Gianantonio Rosti, MD, Institute of Hematology ‘Seragnoli’, Bologna, Italy, discusses the current landscape of chronic myeloid leukemia (CML) treatment, as well as the importance of consistent long-term monitoring. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Gianantonio Rosti

3:15
New horizons in CML
Gianantonio Rosti • 13 Jun 2019
1:55
Long-term monitoring, adherence & endpoints in CML
Gianantonio Rosti • 13 Jun 2019
4:33
Optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia
Gianantonio Rosti • 12 Jun 2015

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals